Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Royalty Pharma PLC (RPRX : NSDQ)

• Company Description    Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. Number of Employees: 100

• Price / Volume Information    Yesterday's Closing Price: $62.15 Daily Weekly Monthly 20 Day Moving Average: 2,983,822 shares Shares Outstanding: 575.00 (millions) Market Capitalization: $35,736.33 (millions) Beta: 0.42 52 Week High: $64.38 52 Week Low: $35.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.81% 7.09% 12 Week 5.02% -0.95% Year To Date 60.84% 41.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 110 East 59th Street - New York,NY 10022 USA ph: 212-883-0200 fax: - ir@royaltypharma.com http://www.royaltypharma.com

• General Corporate Information    Officers Pablo Legorreta - Chairman of the Board; Director & Chief Executive Terrance Coyne - Executive Vice President & Chief Financial Officer Bonnie Bassler - Director Errol De Souza - Director Catherine Engelbert - Director Peer Information Royalty Pharma PLC (CORR.) Royalty Pharma PLC (RSPI) Royalty Pharma PLC (CGXP) Royalty Pharma PLC (BGEN) Royalty Pharma PLC (GTBP) Royalty Pharma PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G7709Q104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/04/26 Share - Related Items Shares Outstanding: 575.00 Most Recent Split Date: (:1) Beta: 0.42 Market Capitalization: $35,736.33 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 1.51% Current Fiscal Quarter EPS Consensus Estimate: $1.53 Indicated Annual Dividend: $0.94 Current Fiscal Year EPS Consensus Estimate: $5.29 Payout Ratio: 0.18 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: -0.03 Estmated Long-Term EPS Growth Rate: 6.90% Last Dividend Paid: 08/14/2026 - $0.23 Next EPS Report Date: 11/04/26

• Fundamental Ratios P/E Current FY Estimate: 11.75 Trailing 12 Months: 11.84 PEG Ratio: 1.70 Price Ratios Price/Book: 3.65 Price/Cash Flow: 13.01 Price / Sales: 14.09 EPS Growth vs. Year Ago Period: 15.79% vs. Previous Quarter: 1.54% Sales Growth vs. Year Ago Period: 16.41% vs. Previous Quarter: 6.81% ROE 09/30/26 - - 06/30/26 - 30.01 03/31/26 - 29.25 ROA 09/30/26 - - 06/30/26 - 14.91 03/31/26 - 14.71 Current Ratio 09/30/26 - - 06/30/26 - 2.80 03/31/26 - 2.66 Quick Ratio 09/30/26 - - 06/30/26 - 2.80 03/31/26 - 2.66 Operating Margin 09/30/26 - - 06/30/26 - 115.54 03/31/26 - 116.14 Net Margin 09/30/26 - - 06/30/26 - 32.14 03/31/26 - 33.88 Pre-Tax Margin 09/30/26 - - 06/30/26 - 53.11 03/31/26 - 55.63 Book Value 09/30/26 - - 06/30/26 - 17.00 03/31/26 - 17.25 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.88 03/31/26 - 0.86 Debt-to-Capital 09/30/26 - - 06/30/26 - 46.72 03/31/26 - 46.33

Powered by Zacks Investment Research ©